1.
McPhee JT, Hill JS, Whalen GF, et al.:
Perioperative mortality for
pancreatectomy: a national perspective. Ann Surg 2007; 246(2): 246-53.
2.
Iida H, Tani M, Maehira H, et al.:
Postoperative Pancreatic Swelling Predicts
Pancreatic Fistula after Pancreaticoduodenectomy.
321-326.
Am Surg 2019; 85(4):
rP
3.
Fo
Watanabe Y, Nishihara K, Matsumoto S, et al.: Effect of postoperative major
ee
complications on prognosis after pancreatectomy for pancreatic cancer: a
rR
retrospective review. Surg Today 2017; 47(5): 555-567.
4.
ev
Kawai M, Murakami Y, Motoi F, et al.: Grade B pancreatic fistulas do not affect
iew
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
The American Surgeon
survival after pancreatectomy for pancreatic cancer: A multicenter observational
study.
5.
Surgery 2016; 160(2): 293-305.
Dindo D, Demartines N, Clavien PA:
Classification of surgical complications: a
new proposal with evaluation in a cohort of 6336 patients and results of a survey.
Ann Surg 2004; 240(2): 205-13.
6.
John BJ, Wijeyekoon S, Warnaar N, et al.:
Biochemical indicators of in-hospital
complications following pancreatic surgery.
Int Surg 2010; 95(3): 215-20.
https://mc.manuscriptcentral.com/americansurgeon
The American Surgeon
7.
Welsch T, Frommhold K, Hinz U, et al.:
Persisting elevation of C-reactive protein
after pancreatic resections can indicate developing inflammatory complications.
Surgery 2008; 143(1): 20-8.
8.
Oettle H, Neuhaus P, Hochhaus A, et al.: Adjuvant chemotherapy with gemcitabine
and long-term outcomes among patients with resected pancreatic cancer: the
CONKO-001 randomized trial. JAMA 2013; 310(14): 1473-81.
Uesaka K, Boku N, Fukutomi A, et al.:
rP
9.
Fo
Adjuvant chemotherapy of S-1 versus
gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised,
ee
non-inferiority trial (JASPAC 01). Lancet 2016; 388(10041): 248-57.
rR
10. Kantor O, Talamonti MS, Stocker SJ, et al.:
A Graded Evaluation of Outcomes
ev
Following Pancreaticoduodenectomy with Major Vascular Resection in Pancreatic
iew
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Page 16 of 18
Cancer. J Gastrointest Surg 2016; 20(3): 284-92.
11. DeOliveira ML, Winter JM, Schafer M, et al.:
Assessment of complications after
pancreatic surgery: A novel grading system applied to 633 patients undergoing
pancreaticoduodenectomy. Ann Surg 2006; 244(6): 931-7.
12. Forrest LM, McMillan DC, McArdle CS, et al.:
Evaluation of cumulative
prognostic scores based on the systemic inflammatory response in patients with
inoperable non-small-cell lung cancer.
Br J Cancer 2003; 89(6): 1028-30.
https://mc.manuscriptcentral.com/americansurgeon
Page 17 of 18
13. Toiyama Y, Miki C, Inoue Y, et al.:
Evaluation of an inflammation-based
prognostic score for the identification of patients requiring postoperative adjuvant
chemotherapy for stage II colorectal cancer.
Exp Ther Med 2011; 2(1): 95-101.
14. Schlick K, Magnes T, Huemer F, et al.:
C-Reactive Protein and
Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling overall survival
Prediction in Pancreatic Cancer Patients. J Clin Med 2019; 8(11): 1791
Fo
15. Onoe S, Maeda A, Takayama Y, et al.:
rP
The Prognostic Impact of the
Lymphocyte-to-Monocyte Ratio in Resected Pancreatic Head Adenocarcinoma.
ee
Med Princ Pract 2019; 28(6): 517-525.
16. Nakazaki H:
rR
Preoperative and postoperative cytokines in patients with cancer.
Cancer 1992; 70(3): 709-13.
iew
17. Wakuda R, Miki C,Kusunoki M:
ev
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
The American Surgeon
Autoreactivity against interleukin 6 as a risk
factor in elderly patients with colorectal carcinoma.
Arch Surg 2001; 136(11):
1274-9.
18. Nozoe T, Matsumata T, Sugimachi K: Preoperative elevation of serum C-reactive
protein is related to impaired immunity in patients with colorectal cancer.
Am J
Clin Oncol 2000; 23(3): 263-6.
19. Xu W, Peng X, Jiang B:
Hypoalbuminemia after pancreaticoduodenectomy does
https://mc.manuscriptcentral.com/americansurgeon
The American Surgeon
not predict or affect short-term postoperative prognosis.
BMC Surg 2020; 20(1):
72.
iew
ev
rR
ee
rP
Fo
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Page 18 of 18
https://mc.manuscriptcentral.com/americansurgeon
Page 19 of 18
Figure Legends
Figure 1. Relationship between the grade on the Clavien-Dindo classification and the white blood
cell and lymphocyte counts as well as C-reactive protein level on postoperative day 7. *; p=0.027
(none vs. grade IVa), **; p=0.002 (none vs. grade IIIa/b).
Figure 2. The Kaplan-Meyer curve was shown divided into 2 groups (CRP-low and presence of
Fo
adjuvant chemotherapy; solid line versus CRP-high and no adjuvant chemotherapy; break line), and
rP
2 curve is divergent, suggesting that the patients with CRP-high and no adjuvant chemotherapy had
poor survival factors .
iew
ev
rR
ee
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
The American Surgeon
https://mc.manuscriptcentral.com/americansurgeon
Table 1.
The characteristics of patients
Parameter
Age (years old) *
Gender (male/female)
Body mass index (kg/m2) *
Diabetes mellitus
Biliary drainage
T factor (0/1/2/3)
N factor (0/1/2)
Hemoglobin (g/dL) *
WBC (x10３μL) *
Lymphocyte (x10３μL) *
Albumin (g/dL) *
C-reactive protein (mg/dL) *
modified Glasgow prognostic score (0/1/2)
CEA (ng/mL)**
CA19-9 (U/mL)**
68.5 (9.47)
63/45
21.47 (3.85)
46 (42.6%)
35 (32.9%)
1/4/5/98
35/71/2
12.2 (1.68)
5.4 (1.59)
1.26 (1.508)
3.6 (0.44)
0.58 (1.11)
93/7/8
4.00 (0.9, 30.4)
79.00 (1, 3315)
Preoperative chemo(radio)therapy
21 (19.4%)
; mean (standard deviation), **; median (range)
WBC ;white blood cells, CEA; carcinoembryonic antigen, CA19-9; carbohydrate
antigen 19-9,
Table 2. The perioperative and postoperative characteristics of patients
Parameter
Operative procedures (PD/DP/TP)
Portal vein resection (yes)
Operative time (min.) **
Estimate blood loss (mL) **
Blood transfusion (yes)
WBC on POD7 (x10３μL) *
Lymphocyte on POD7 (x10３μL) *
Albumin on POD7
(g/dL) *
C-reactive protein on POD7 (mg/dL) *
The Clavien-Dindo classification (grade I/II/IIIa/IIIb/IVa/V)
64/33/11
32 (29.6%)
486.5 (199, 853)
855.5 (20, 10208)
32 (29.6%)
8.7 (3.15)
1.03 (0.43)
2.7 (0.40)
5.36 (3.90)
6/35/24/2/8/0
Adjuvant chemotherapy (yes)
77 (71.3%)
; mean (standard deviation), **; median (range)
PD;pancreaticoduodenectomy, DP; distalpancreatectomy, TP; total pancreatectomy,
WBC ;white blood cells, POD; postoperative days
Table 3. The comparison inflammatory biomarkers divided into the categorized CD
classification.
The CD classification
Grade 0/I/II
Preoperative examinations
WBC (x10３μL)
5.38 (1.59)
Lymphocyte (x10 μL)
1.55 (0.58)
C-reactive protein (mg/dL)
.51 (1.14)
Postoperative examinations on postoperative day 7
WBC (x10３μL)
8.27 (2.93)
Lymphocyte (x10 μL)
1.05 (0.44)
C-reactive protein (mg/dL)
4.95 (4.23)
CD; Clavien-Dindo
WBC; white blood cell,
p-value
Grade III/IV
5.50 (1.57)
1.62 (0.68)
.63 (1.06)
.719
.569
.622
9.55 (3.48)
0.99 (0.41)
6.26 (2.92)
.067
.554
.107
Table 4.
The univariate and multivariate analysis on the survival after pancreatic
resection.
Univariate analysis
Predictor
HR
T factor (0/1)
.185
LN metastases
95% CI
Multivariate analysis
p-value
HR
95% CI
p-value
.026-1.353
0.094
.165
.023-1.208
.076
1.309
.781-2.193
.307
1.30
.747-2.252
.356
NAC
1.073
.574-2.006
.825
1.119
.591-2.119
.730
Adjuvant chemotherapy
.429
.259-.71
.001
.389
.227-.667
<.001
CD classification (0/I/II)
.770
.482-1.285
.317
.966
.555-1.681
.903
WBC on POD7 (>9.9)
1.230
.724-2.089
.444
.990
.558-1.756
.972
Lymphocyte on POD7 (>8.5)
.777
.396-1.526
.464
.526
.255-1.086
.083
CRP on POD7 (>7.6)
1.020
.962-1.083
.504
1.095
Albumin on POD7 (>2.5)
.618
.358-1.065
.083
.610
1.023-1.174 .009
.333-1.115
.108
HR; hazard ratio (HR), CI; confidence interval,
LN; lymph node, NAC; neoadjuvant chemotherapy, CD; Clavien-Dindo, WBC; white
blood cell, POD; postoperative day, CRP; C-reactive protein
...
論文の公開元へ
